Latest Headlines

Latest Headlines

Isis is in the spotlight--and maybe crosshairs--after gene breakthrough

Antisense specialist Isis Pharmaceuticals has made it all the way to mid-stage trials with ISIS-APOCIII, targeting patients with a rare ailment that leads to dangerously high triglycerides. But that candidate is looking all the more promising in light of two major studies linking its target to reduced rates of heart attack, saddling the biotech with a potential blockbuster.

Bristol-Myers toes the next hep C frontier: a four-week cure

Gilead Sciences' Sovaldi has broken sales records thanks to its ability to cure hepatitis C with an effective, if costly, 12-week regimen. But rivals believe there's plenty of room in the market for a speedier solution, and Bristol-Myers Squibb plans to use its ex-partner's blockbuster to craft a four-week contender.

After three strikes, Sanofi gives up on Merrimack's cancer drug

Sanofi is breaking it off with oncology partner Merrimack Pharmaceuticals, handing back full rights to MM-121, a treatment that has three times failed to hit the mark in midstage studies.

Kite Pharma rides the CAR-T current to a $128M IPO

Biotech upstart Kite Pharma made its Wall Street debut Friday, pulling off an upsized IPO on the strength of investor fervor over a novel, headline-making approach to treating cancer.

J&J Innovation spotlights its slate of new biotech deals

When Johnson & Johnson Innovation debuted about a year ago, R&D chief Paul Stoffels promised to build an interconnected, global operation that would sink some deep roots into the world's busiest biotech hubs. On Thursday, the group showed off just how far it had come in a short time.

Scripps chief says patients' interests are med tech's biggest challenge

Head of the Scripps Translational Science Institute Eric Topol--a distinguished cardiologist and genomic researcher--says that med tech can make medicine more transparent, as well as help patients make more informed decisions.

J&J Innovation shows off its new summer lineup of biotech deals

Johnson & Johnson Innovation has announced a slate of a dozen new deals, ranging from fresh research collaborations to new investments in a range of upstart drug and device developers--all aimed at putting the multinational pharma giant on the cutting edge of new product development.

Navitor grabs a $23.5M A round to tackle a key crossroad for disease

A little more than a year ago, GlaxoSmithKline disbanded George Vlasuk's team at Sirtris and absorbed the R&D work in its Pennsylvania operations. But that didn't end the relationship. Today Vlasuk is back at the helm of a new biotech dubbed Navitor Pharmaceuticals, which was seeded initially by Polaris and is now coming out of stealth mode with a $23.5 million Series A and the backing of a syndicate that includes SR One, GlaxoSmithKline's venture arm.

Meet the new Novartis: Slimmer structure, same R&D commitment

Novartis, the industry's largest employer, is flipping units and streamlining its operation to boost margins, but the company has no plans to take its foot off the gas in R&D, keeping the pace on a $10-billion-a-year research budget with hopes of cranking out 14 blockbusters by 2018.

'Onion' drug delivery vehicle has concentric layers for consistent dosing

A new type of drug delivery vehicle from the University of Pennsylvania is made up of several membranes layered on each other to protect the drug at its core or possibly deliver a few different drugs over time.